
Korea holds back on Lilly’s Mounjaro and Novo’s Ozempic as Thailand moves ahead
Eli Lilly’s Mounjaro (tirzepatide) is hitting pharmacy shelves in Thailand this week. In Korea, where both diabetes and obesity indications were approved nearly a year ago, the dual-action GLP-1 and GIP agonist is still stuck in regulatory limbo with no …